Mitchell Capital Management Co. Purchases New Position in Moderna, Inc. (NASDAQ:MRNA)

Mitchell Capital Management Co. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 900 shares of the company’s stock, valued at approximately $211,000.

A number of other institutional investors also recently made changes to their positions in the business. TCI Wealth Advisors Inc. boosted its position in Moderna by 10.0% during the second quarter. TCI Wealth Advisors Inc. now owns 318 shares of the company’s stock worth $75,000 after purchasing an additional 29 shares during the period. Western Wealth Management LLC boosted its position in Moderna by 3.2% during the second quarter. Western Wealth Management LLC now owns 1,591 shares of the company’s stock worth $376,000 after purchasing an additional 49 shares during the period. Optimum Investment Advisors boosted its position in Moderna by 14.3% during the second quarter. Optimum Investment Advisors now owns 400 shares of the company’s stock worth $94,000 after purchasing an additional 50 shares during the period. Parallel Advisors LLC boosted its position in Moderna by 2.0% during the second quarter. Parallel Advisors LLC now owns 3,359 shares of the company’s stock worth $789,000 after purchasing an additional 67 shares during the period. Finally, Evolution Wealth Advisors LLC boosted its position in Moderna by 107.1% during the second quarter. Evolution Wealth Advisors LLC now owns 145 shares of the company’s stock worth $34,000 after purchasing an additional 75 shares during the period. 55.89% of the stock is owned by hedge funds and other institutional investors.

NASDAQ MRNA opened at $427.71 on Wednesday. The firm has a market cap of $172.64 billion, a P/E ratio of 53.33, a P/E/G ratio of 0.53 and a beta of 1.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.24 and a quick ratio of 1.17. The stock’s 50-day moving average is $365.45 and its 200-day moving average is $238.96. Moderna, Inc. has a one year low of $63.64 and a one year high of $497.49.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 5th. The company reported $6.46 EPS for the quarter, topping the Zacks’ consensus estimate of $6.01 by $0.45. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.23 billion. Moderna had a return on equity of 88.13% and a net margin of 49.79%. Moderna’s revenue was up 6457.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.31) earnings per share. Equities analysts anticipate that Moderna, Inc. will post 29.17 EPS for the current year.

In other Moderna news, insider Juan Andres sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 21st. The stock was sold at an average price of $200.86, for a total transaction of $1,004,300.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $1,004,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $447.41, for a total value of $8,948,200.00. The disclosure for this sale can be found here. In the last three months, insiders sold 325,000 shares of company stock worth $108,460,200. 19.40% of the stock is owned by insiders.

A number of equities research analysts have issued reports on the company. Chardan Capital reaffirmed a “buy” rating on shares of Moderna in a research report on Wednesday, July 7th. Jefferies Financial Group increased their price objective on Moderna from $170.00 to $250.00 and gave the company a “hold” rating in a research report on Thursday, July 15th. They noted that the move was a valuation call. Zacks Investment Research cut Moderna from a “buy” rating to a “hold” rating and set a $330.00 price objective for the company. in a research report on Monday, July 19th. TheStreet cut Moderna from a “b” rating to a “c+” rating in a research report on Friday, June 11th. Finally, Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 5th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $205.21.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Article: What does a dividend yield signify to investors?

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.